Working… Menu
Trial record 42 of 451 for:    QUETIAPINE

A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01165541
Recruitment Status : Completed
First Posted : July 20, 2010
Results First Posted : March 31, 2014
Last Update Posted : April 9, 2018
Information provided by (Responsible Party):
Alan Green, Dartmouth-Hitchcock Medical Center

Brief Summary:
The purpose of the study is to test whether taking two medicines (quetiapine and mirtazapine) is better for helping people to decrease drinking than taking one medicine alone (quetiapine).

Condition or disease Intervention/treatment Phase
Alcohol Dependence Drug: Mirtazapine Drug: Quetiapine fumarate extended release (Quetiapine XR) Phase 2

Detailed Description:

Alcohol dependence is a debilitating illness affecting almost 8 million people annually and for which the current FDA approved medications are only modestly effective in reducing relapse or drinking. Because alcohol dependence is such a common, devastating disease, researchers continue to search for new treatments that could be more effective and better tolerated. The development and testing of medications that target brain systems involved in alcohol dependence is of acute interest to patients, clinicians and researchers.

Studies by our group in animals have suggested that medications with a combination of a weak dopamine D2 receptor antagonism, a potent norepinephrine alpha 2 receptor antagonism, and norepinephrine reuptake inhibition decrease alcohol drinking. Quetiapine is a weak D2 antagonist and a moderate alpha 2 receptor antagonist, and its primary metabolite, desalkylquetiapine, is a norepinephrine reuptake inhibitor, this medication is likely to have some ability to decrease alcohol drinking. But, when combined with mirtazapine, a potent alpha 2 antagonist, the combination should potently decrease alcohol drinking. The proposed study is based on this theoretical formulation, as well as on clinical studies of quetiapine and mirtazapine used independently.

This is an open-label, sequential design study with one group of approximately 20 subjects studied under two treatment conditions; quetiapine alone and quetiapine + mirtazapine. The primary objective is to assess the efficacy of quetiapine fumarate extended-release (XR) alone vs. quetiapine fumarate XR in combination with mirtazapine in reducing the weekly percentage of days of heavy drinking (5 or more drinks per drinking day for men, 4 or more drinks per drinking day for women) in subjects meeting DSM-IV criteria for alcohol dependency.

Participants will begin with quetiapine fumarate XR up to a target dose of 400 mg and will receive 16 weeks of treatment with quetiapine. At week 8 subjects will begin 9 weeks of mirtazapine added to their existing regimen of quetiapine treatment. Participants will also meet with a medical provider at each visit to encourage compliance with study medication and attending study visits, review adverse events, and set goals for reduction of drinking. Analyses will assess whether treatment with quetiapine in combination with mirtazapine reduces drinking more than treatment with quetiapine alone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Sequential Study of Quetiapine Fumarate Extended Release (XR) and Mirtazapine for the Treatment of Alcohol Dependency in Very Heavy Drinkers
Study Start Date : September 2010
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Quetiapine fumarate extended release (Quetiapine XR)
Quetiapine XR 50-400mg
Drug: Quetiapine fumarate extended release (Quetiapine XR)
Quetiapine fumarate extended release 50-400mg/d
Other Name: quetiapine XR, Seroquel XR

Experimental: Quetiapine XR and Mirtazapine
Quetiapine XR 50-400mg + Mirtazapine 7.5-45mg
Drug: Mirtazapine
mirtazapine (7.5-45mg)
Other Name: mirtazapine (Remeron)

Drug: Quetiapine fumarate extended release (Quetiapine XR)
Quetiapine fumarate extended release 50-400mg/d
Other Name: quetiapine XR, Seroquel XR

Primary Outcome Measures :
  1. Number of Very Heavy Drinking Days Per Week [ Time Frame: 14 Weeks ]
    The number of "very heavy" drinking days (8 or more drinks per drinking day for men or 6 or more drinks per drinking day for women) per week

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18-64
  2. The subject meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for alcohol dependence
  3. The subject is seeking treatment for alcohol dependence and desires a reduction or cessation of drinking
  4. The subject is able to verbalize understanding of the consent form, able to provide written informed consent, and able to verbalize willingness to complete study procedures?
  5. If the subject is female and of child bearing potential, she agrees to use an acceptable method of birth control.
  6. The subject is able to take oral medication, willing to adhere to the medication regimen, and willing to return for regular visits.
  7. The subject is able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
  8. The subject has a breath alcohol concentration (BAC) equal to 0.000 on s/he signing the informed consent document.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01165541

Layout table for location information
United States, New Hampshire
Dartmouth Medical School Department of Psychiatry's Addition Research Center
Bedford, New Hampshire, United States, 03110
Dartmouth Medical School Department of Psychiatry's Addiction Research Center
Hanover, New Hampshire, United States, 03755
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Layout table for investigator information
Principal Investigator: Mary Brunette, MD Dartmouth-Hitchcock Medical Center

Layout table for additonal information
Responsible Party: Alan Green, Principal Investigator, Dartmouth-Hitchcock Medical Center Identifier: NCT01165541     History of Changes
Other Study ID Numbers: QM1
First Posted: July 20, 2010    Key Record Dates
Results First Posted: March 31, 2014
Last Update Posted: April 9, 2018
Last Verified: March 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Quetiapine Fumarate
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Adrenergic alpha-2 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Serotonin Agents
Serotonin 5-HT3 Receptor Antagonists